BAY 20321 An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies
Laufzeit: 01.01.2020 - 31.12.2023
Kurzfassung
Weiterbehandlungder Patienten mit CRPC aus der Studie ARAMIS
Gabe von Darolutamide
